Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Investing Activities: 2011-2024

Historic Cash from Investing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $363.4 million.

  • Agios Pharmaceuticals' Cash from Investing Activities fell 61.90% to $95.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.9 million, marking a year-over-year decrease of 53.17%. This contributed to the annual value of $363.4 million for FY2024, which is 51.70% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Cash from Investing Activities of $363.4 million as of FY2024, which was up 51.70% from $239.6 million recorded in FY2023.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities peaked at $1.2 billion during FY2021, and registered a low of $76.5 million during FY2020.
  • For the 3-year period, Agios Pharmaceuticals' Cash from Investing Activities averaged around $282.1 million, with its median value being $243.3 million (2022).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash from Investing Activities soared by 1,531.34% in 2021, and later crashed by 80.52% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Investing Activities (Yearly) stood at $76.5 million in 2020, then surged by 1,531.34% to $1.2 billion in 2021, then slumped by 80.52% to $243.3 million in 2022, then fell by 1.52% to $239.6 million in 2023, then skyrocketed by 51.70% to $363.4 million in 2024.